Clinical Trial

NeurAxis Reports Second Quarter 2023 Financial Results

CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company…

1 year ago

Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related…

1 year ago

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage…

1 year ago

Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achievedMedia Release SYDNEY, AUSTRALIA, Sept. 21, 2023 (GLOBE NEWSWIRE)…

1 year ago

CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis

AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation Data will be used to…

1 year ago

Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium

All three Fanconi Anemia patients treated with briquilimab achieved full donor engraftment and full blood count recoveryBriquilimab was well tolerated…

1 year ago

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today…

1 year ago

New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program

- 850 cancer cell lines screened in Broad Institute’s PRISM lab - - Rencofilstat active on 220 cancer cell lines…

1 year ago

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

BOSTON and LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a late-stage…

1 year ago

PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health

Successful Audit of the Company’s State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to Commercialize D-PLEX₁₀₀ GloballyPETACH TIKVA, Israel,…

1 year ago